09:14 AM EDT, 08/11/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) said Monday it has signed a deal, through its Huge Biopharma Australia unit, with an unnamed contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS.

The company will use the oral formulation of Lucid-MS, a non-immunomodulatory, neuroprotective compound, in its upcoming phase 2 multiple sclerosis study, Quantum added.

The biopharmaceutical company said its phase 2 trial will evaluate the efficacy of Lucid-MS on human participants for the possible treatment of regaining mobility lost due to multiple sclerosis.

Shares of the company were up 6% in recent Monday premarket activity.